RedHill's Opaganib Shows Promise in Neuroblastoma and Triple-Negative Breast Cancer Studies at AACR 2026

Key Takeaways

• Opaganib enhanced the efficacy of chemotherapy combinations in neuroblastoma preclinical models
• The drug augmented anti-tumor immunity in triple-negative breast cancer studies
• Independent research teams presented positive data at the 2026 AACR Annual Meeting

---

RedHill Biopharma’s Opaganib Advances Cancer Research

RedHill Biopharma announced positive preclinical results for opaganib as a potential add-on therapy for two aggressive cancer types, with data presented at the 2026 American Association for Cancer Research (AACR) Annual Meeting. Independent research teams demonstrated the drug’s potential in neuroblastoma and triple-negative breast cancer models.

Neuroblastoma Research Shows Enhanced Treatment Efficacy

The neuroblastoma studies, conducted by Penn State University’s Jeremy Hengst and Apogee Biotechnology with funding from the Beat Childhood Cancer Foundation and Four Diamonds, revealed that opaganib may enhance the effectiveness of existing chemotherapy combinations. Neuroblastoma is a rare but aggressive pediatric cancer that primarily affects children under five years old.

The research suggests opaganib could serve as an adjunctive therapy, potentially improving outcomes for young patients facing this challenging diagnosis. Current neuroblastoma treatments often involve intensive chemotherapy regimens, and any enhancement to their efficacy could significantly impact patient survival rates.

Triple-Negative Breast Cancer Immunity Benefits

Separate studies demonstrated opaganib’s ability to augment anti-tumor immunity in triple-negative breast cancer (TNBC) models. TNBC represents approximately 15% of all breast cancers and is characterized by its aggressive nature and limited treatment options compared to hormone receptor-positive breast cancers.

The immune system enhancement observed in preclinical models suggests opaganib could potentially work alongside immunotherapy approaches, offering new hope for TNBC patients who currently face fewer targeted treatment options.

Market Implications and Next Steps

These positive preclinical results position opaganib as a potential multi-indication cancer therapy. The drug’s ability to show efficacy across different cancer types and mechanisms—enhancing chemotherapy in neuroblastoma and boosting immunity in TNBC—demonstrates its versatility as a cancer treatment platform.

RedHill Biopharma will likely use this data to support future clinical trial applications and regulatory discussions. The independent nature of the research, conducted by academic institutions and funded by cancer foundations, adds credibility to the findings and may facilitate partnerships for further development.

---

Frequently Asked Questions

What does this mean for patients with neuroblastoma or triple-negative breast cancer?

These are early preclinical studies, so opaganib is not yet available for patient treatment. However, the positive results suggest potential future treatment options that could enhance existing therapies for both cancer types.

When will opaganib be available for cancer patients?

The drug is still in preclinical development for these cancer indications. Clinical trials in humans would need to be conducted and regulatory approval obtained before it becomes available to patients, which typically takes several years.

How does opaganib work differently in neuroblastoma versus triple-negative breast cancer?

In neuroblastoma models, opaganib enhanced the efficacy of chemotherapy combinations, while in TNBC models, it augmented anti-tumor immunity. This suggests the drug may have multiple mechanisms of action across different cancer types.